Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly p...
Saved in:
Main Authors: | Yael Rachamin, Christoph Jakob Ackermann, Oliver Senn, Thomas Grischott |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7cceb14eaa2541c6b333e1e614f3fbb9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
by: Yael Rachamin, et al.
Published: (2021) -
Change in Colorectal Cancer Tests Submitted for Reimbursement in Switzerland 2012–2018: Evidence from Claims Data of a Large Insurance
by: Rémi Schneider, et al.
Published: (2021) -
The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
by: Lux MP, et al.
Published: (2021) -
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
by: Khadidja Abdallah, et al.
Published: (2021) -
Geography of medication reimbursements in Belgium: an exploratory analysis
by: Sonia Trabelsi, et al.
Published: (2021)